Social Safety Learning in the Brain Oxytocin System

Status Recruiting

Clinical Trial Summary

The investigators are conducting this research study to examine whether oxytocin enhances social safety learning (learning safety through the experience of another individual) in people with social anxiety disorder (SAD) compared to healthy volunteers. Oxytocin is a hormone that can also act as a chemical messenger in the brain. Oxytocin plays a role in a number of functions, including responding to fear and social interactions. In this study, the investigators would like to compare the effects of oxytocin and placebo nasal sprays in adults with SAD and healthy adults. This research study will compare an oxytocin nasal spray to a placebo nasal spray. About 120 people will take part in this research study, all at the University of Washington (UW).

Clinical Trial Description

The goal of the current study is to examine the potential role of oxytocin in enhancing social learning in SAD. The investigators' primary hypothesis is that vicarious extinction learning will contribute to safety learning and that oxytocin will potentiate vicarious extinction learning in patients with SAD, compared to healthy controls (HC). The investigators will directly test the effect of intranasal oxytocin and matching placebo on the brain mechanisms underlying vicarious extinction learning using a novel task. 60 adults with SAD and 60 healthy control participants will perform a task that involves three phases: (i) a standard social fear acquisition procedure while in a mock scanner, followed by (ii) a vicarious extinction and (iii) fear reinstatement test procedure, while being scanned during functional magnetic resonance imaging (fMRI). Participants will receive oxytocin or placebo prior to the extinction phase. The investigators will also measure skin conductance responses as an index of learning in each phase. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05968651
Study type	Interventional
Source	University of Washington
Contact	Jessica Crane
Phone	206-221-1278
Email	jcrane2@uw.edu
Status	Recruiting
Phase	Phase 2
Start date	June 26, 2023
Completion date	January 1, 2025

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02256566` - Cognitive Training for Mood and Anxiety Disorders	N/A
Completed	`NCT01570400` - Treatment of Social Phobia With Combined Cognitive Bias Modification and iCBT	N/A
Recruiting	`NCT01388231` - Transfer of Manualized Cognitive-Behavioral Therapy (CBT) for Social Phobia Into Clinical Practice	Phase 2/Phase 3
Completed	`NCT00684541` - Interpretation Modification Program for Social Phobia	N/A
Completed	`NCT00434759` - Social Phobia Intervention Study of Mannheim	N/A
Completed	`NCT00380731` - Effect of Behavior Therapy on Responses to Social Stimuli in People With Social Phobia	N/A
Completed	`NCT03647605` - Pilot Study: VR Mind and VR Mind+ Intervention	N/A
Not yet recruiting	`NCT03241277` - Nonsurgical Periodontal Treatment in Patients With Social Phobia	N/A
Completed	`NCT02648737` - Cognitive Behavioural Therapy for Anxiety Disorders in PD	N/A
Completed	`NCT02294409` - Manualized Group Cognitive-behavioral Therapy for Social Anxiety in First Episode Psychosis	N/A
Terminated	`NCT01979263` - Attention Bias Modification Treatment for Anxious Youth	N/A
Completed	`NCT01463137` - Attention Bias Modification Training in Social Phobia/Social Anxiety Disorder	N/A
Completed	`NCT00774150` - Transdisciplinary Studies of CBT for Anxiety in Youth: Child Anxiety Treatment Study	N/A
Completed	`NCT00264654` - Long-term Study Of Paroxetine in Women and Men	Phase 3
Completed	`NCT00326430` - Residential Cognitive and Interpersonal Therapy for Social Phobia	Phase 2/Phase 3
Completed	`NCT00000389` - Treatment for Anxiety in Children	Phase 3
Completed	`NCT00397722` - Treatment Of Patients With Social Anxiety Disorder	Phase 2
Completed	`NCT02678624` - Project Collabri for Treatment of Anxiety	N/A
Completed	`NCT00564967` - A Comparison Between Internet Therapy and Group Therapy for Social Phobia - A Trial Using Cognitive Behavioural Therapy	Phase 3
Completed	`NCT00403962` - A Combination Therapy In Patients With Social Anxiety Disorder	Phase 2